Clinical Trials Directory

Trials / Completed

CompletedNCT03794271

Effect of Pupilometer Guided Analgesia on Postoperative Pain

Effect of Pupilometer Guided Analgesia on Postoperative Pain Intensity and Perioperative Complications

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
84 (actual)
Sponsor
Daegu Catholic University Medical Center · Academic / Other
Sex
All
Age
20 Years – 65 Years
Healthy volunteers
Not accepted

Summary

In this study, the investigators measure a pupil size every 5 minutes during the operation in patients undergoing laparoscopic cholecystectomy under general anesthesia. The investigators would compare the postoperative pain intensity between the group adjusted the anesthetic drug concentration based on the changes of the pupil (Pupil group) and the group based on the changes of a surgical pleth index (SPI group).

Conditions

Interventions

TypeNameDescription
PROCEDUREPupilometer guided anesthesiaAt least 10 min after anesthesia induction by target-controlled infusion of propofol and remifentanil, baseline values for pupillary diameter is recorded before any surgical procedure. During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60. Remifentanil Ce is adapted every 5 min based on the changes of pupillary diameter. If the pupillary diameter is increased by more than 30% compared to baseline value, remifentanil concentration is increased by 0.5 ng/ml. If the pupillary diameter is maintained between 5 and 30 % change compared with baseline, remifentanil is not modified. In a case of pupillary diameter is decreased less than 5 % change of baseline, remifentanil concentration is decreased by 0.5 ng/ml.
PROCEDURESPI guided anesthesiaDuring the operation, SPI value should be maintained between 20 and 50 by changing the infusion rate of remifentanil. Even if the SPI is maintained within the target range, the remifentanil infusion rate is increased by 0.5 ng/ml in a case of the SPI value suddenly arises by more than 10.

Timeline

Start date
2019-01-03
Primary completion
2019-05-09
Completion
2019-05-10
First posted
2019-01-07
Last updated
2019-08-12

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT03794271. Inclusion in this directory is not an endorsement.